Background

The EMBRACE study is a collaborative research initiative focused on advancing image-guided adaptive brachytherapy (IGABT) for locally advanced cervical cancer. Initiated in 2008 by the GEC-ESTRO Working Group, EMBRACE aims to improve clinical outcomes by refining and standardizing IGABT techniques .  

The study has achieved significant milestones, including the completion of EMBRACE I, a prospective observational study that enrolled 1416 patients and provided a large dataset for analysis . This led to the launch of EMBRACE II, an ongoing prospective interventional study that incorporates specific treatment strategies based on findings from EMBRACE I and the retrospective retroEMBRACE study .  

EMBRACE has had a profound impact on the field of radiation oncology. It has promoted standardized contouring, reporting, and dose prescription practices, leading to a better understanding of IGABT and improved clinical outcomes . The study has also provided evidence for dose de-escalation strategies to minimize treatment-related side effects . Furthermore, EMBRACE has generated numerous publications in high-impact medical journals, contributing significantly to the understanding of IGABT in locally advanced cervical cancer and influencing clinical practice and research directions .

EMBRACE-III

The EMBRACE-III Triplet Study builds upon the success of its predecessors, EMBRACE-I and EMBRACE-II, which have significantly advanced our understanding of cervical cancer treatment.